Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration

Back to results

Primary Purpose

Status

Completed

Phase

Phase 2

Locations

Germany

Study Type

Interventional

Intervention

Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified

Albumin (Human) 25%, United States Pharmacopeia (USP)

About this trial

This is an interventional treatment trial for Macular Degeneration

Eligibility Criteria

51 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: The best corrected visual acuity must be in the range of 20/40 to 20/200 on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart (0.5 - 0.1). Patient complaint of visual loss within the last three months prior to study entry. Documented visual loss on a visual acuity chart in the 3-month period prior to the beginning of the run-in period. Signed written informed consent prior to initiation of any study-related procedures. Exclusion Criteria: Treatment with IGIV within the last 3 months prior to the run-in. Previous photodynamic therapy (PDT) or vitrectomy or transpupillary thermotherapy (TTT) or any specific pre-treatment of CNV Subfoveal blood in the study eye if ≥ 1/2 disc diameter as measured by slit lamp during run-in period. History of anaphylaxis or severe systemic response to immunoglobulin or with a blood product. Cardiac insufficiency (NYHA III/IV), cardiomyopathy, significant cardiac dysrhythmia requiring treatment, unstable or advanced ischemic heart disease, or severe or uncontrolled hypertension (diastolic > 95 mmHg or systolic >170 mmHg) Females, who are pregnant, breast feeding, or if of childbearing potential, unwilling to practice adequate contraception throughout the study. History of renal insufficiency or serum creatinine levels > 221 µmol/L (2.5 mg/dL). Known selective immunoglobulin A (IgA) deficiency Other investigational drugs received within the past 3 months. Conditions whose symptoms and effects could alter protein catabolism and/or immunoglobulin (IgG) utilization (e.g. protein-losing enteropathies, nephrotic syndrome). Known hypercoagulable state. Patients on continuous systemic steroid treatment Mentally challenged adult subjects who cannot give independent informed consent. History of thromboembolic events. Diabetes mellitus requiring drug treatment. Known severe hypersensitivity to sodium fluorescein. Acute or known ocular diseases such as glaucoma, arterial or venous occlusions, acute ischemic optic-neuropathy, impairment of visual acuity due to opacities in the lens (LOCSIII: NO 5-6 or C: 4-5 or P 4-5) or vitreous which may influence the evaluation of the therapeutic effect.

Sites / Locations

Universitatsklinikum Aachen, Augenklinik
Augenklinik Tausendfensterhaus
St. Martinus-Krankenhaus, Augenabteilung
Medizinische Eirnrichtungen der Universitat Essen, Klinik fur Erkrankungen des hinteren Augenabschnittes
Kliniken und Polikliniken der Albert Ludwigs Universität
Medizinische Einrichtungen der Universitat zu Koln, Centrum fur Augenheilkunde
Klininkum der Eberhard-Karls-Universitat Tubingen, Universitats-Augenklinik

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Group 1

Group 2

Arm Description

Outcomes

Primary Outcome Measures

Mean Change in Visual Acuity (Logarithm of the Minimum Angle of Resolution [LogMAR]) Score From Baseline for IGIV-C, 10% Compared to Placebo at Week 12 or at Last LogMAR Assessment (Conducted at or After Week 8 of the Treatment Period)

Using the LogMAR score, lower values correspond to higher visual acuity. For example, a visual acuity of 20/20 corresponds to a LogMAR value of zero (0), and a visual acuity of 20/100 corresponds to a LogMAR value of 0.7.

Secondary Outcome Measures

Proportion of Subjects Who Improve Visual Acuity From Baseline to Endpoint by ≥ 0.1 LogMAR

Proportion of Subjects Who Improve Visual Acuity From Baseline to Endpoint by ≥ 0.2 LogMAR

Mean Change in LogRAD Score From Baseline to Endpoint (RADNER Test)

The RADNER test gives not only information about the subject's reading performance, but also about the reading speed (life quality) and the faults while reading. The RADNER reading charts (1, 2, and 3) contain sentences in paragraphs having a range of print sizes starting with the largest print at the top.The subject was randomly assigned one of the RADNER charts, and the charts were different between consecutive visits. The reading distance was 25 cm. The subject's score was corrected for reading speed and errors. The range of possible logRAD scores was from 2.0 (could not read the first paragraph) to -0.2, with higher scores indicating lower reading acuity and lower scores indicating higher reading acuity.

Proportion of Subjects With an Increase ≥ 2 or More Points in Lens Opacity Classification System (LOCS III) for Nuclear Opalescence, Nuclear Color, Cortical Cataract or Posterior Subcapsular Cataract Categories

The LOCS III scale for cortical cataract and posterior subcapsular cataract opacity ranged from 1.0 to 5.0. The LOCS III scale for nuclear opalescence and for nuclear color was 1.0 to 6.0. For all scales, higher values indicate higher opacity, opalescence, or color.

Presence of Fibrosis and Location Assessed by Slit-lamp

Mean Change From Baseline to Endpoint in Size of Lesion (Largest Dimension Relative to Disk Diameter) Assessed by Central Fluorescein Angiogram Reading Center

Full Information

NCT ID

NCT00220805

First Posted

September 14, 2005

Last Updated

February 22, 2016

Sponsor

Grifols Therapeutics LLC

1. Study Identification

Unique Protocol Identification Number

NCT00220805

Brief Title

Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration

Official Title

Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-C, 10% Treatment in Subjects With Pure Occult Choroidal Neovascularization Due to Age Related Macular Degeneration

Study Type

Interventional

2. Study Status

Record Verification Date

February 2016

Overall Recruitment Status

Completed

Study Start Date

January 2004 (undefined)

Primary Completion Date

May 2005 (Actual)

Study Completion Date

May 2005 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Grifols Therapeutics LLC

4. Oversight

Data Monitoring Committee

No

5. Study Description

Brief Summary

This study will evaluate visual improvement in patients treated with Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) or placebo who have Age-Related Macular Degeneration (AMD) with occult Choroidal Neovascularization (CNV).

Detailed Description

The purpose of this trial is to investigate the effect of IGIV-C in subjects suffering from AMD with occult CNV where fewer treatment options exist for patients with this disease form. This study is designed as a randomized, double-blind, parallel group, placebo-controlled prospective trial. Sixty patients, 30 per treatment group, with newly diagnosed pure occult CNV defined by angiography diagnostic criteria will be enrolled. If a subject has more than one eye affected with occult CNV, the eye with the better vision as measured by visual acuity ( Logarithm of the Minimum Angle of Resolution [LogMAR] score) will be entered as the study eye. Patients will be randomized to receive either IGIV-C at a dose of 2 g/kg body weight (bw) over 5 consecutive days or matching placebo. Additional 2 study drug treatment courses (IGIV-C or matching placebo) will be administered every 4 weeks at the same dose of 2 g/kg bw given over 5 days. Subjects' visual acuity will be measured and reported as LogMAR at screening, week 0 (baseline), day 5, week 4, week 8 and week 12. If at anytime during the study the subject's visual acuity worsens by ≥ 2 lines (0.2 on the LogMAR score), then a slit lamp examination will be performed and an angiogram will be conducted; the patient would be discontinued if the worsening is due to some other reason outside of the occult CNV or if the disease has changed from pure occult to the classic or mixed form. Subjects will be evaluated for efficacy (LogMAR score) at endpoint (at week 12 or at last LogMAR assessment at or after week 8, if the subject prematurely discontinues the trial). At the end of the treatment period (week 12), patients will be entered into a 3 month observation period with monthly visual acuity LogMAR score assessments.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Macular Degeneration

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 2

Interventional Study Model

Parallel Assignment

Masking

ParticipantCare ProviderInvestigatorOutcomes Assessor

Allocation

Randomized

Enrollment

96 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Group 1

Arm Type

Experimental

Arm Title

Group 2

Arm Type

Placebo Comparator

Intervention Type

Drug

Intervention Name(s)

Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified

Other Intervention Name(s)

Gamunex®, IGIVnex®, Gaminex, IGIV-C, IGIV-C, 10%, Immune Globulin IV (Human), 10% (IGIV), Immune Globulin IV (Human), 10% by Chromatography Process, IGIV, IVIG, BAY 41-1000, TAL-05-00004, NDC 13533-645-12, NDC 13533-645-15, NDC 13533-645-20, NDC 13533-645-24, NDC 13533-645-71

Intervention Description

The dose per infusion cycle was 2 g/kg body weight over 5 consecutive days (= 4 mL/kg body weight/infusion). The infusion duration was approximately 1.5 - 2 h.

Intervention Type

Drug

Intervention Name(s)

Albumin (Human) 25%, United States Pharmacopeia (USP)

Other Intervention Name(s)

Plasbumin®-20, Plasbumin®-25, Plasbumin®-20 (Low Aluminum), Plasbumin®-25 (Low Aluminum), Albumin (Human) 20%, USP, TAL-05-00007, TAL-05-00008, TAL-05-00024, TAL-05-00025, BAY 34-9255, NDC 13533-683-20, NDC 13533-683-71, NDC 13533-684-16, NDC 13533-684-20, NDC 13533-684-71, NDC 13533-691-20, NDC 13533-691-71, NDC 13533-692-16, NDC 13533-692-20, NDC 13533-692-71

Intervention Description

Albumin (Human) 20% or 25% will be diluted with 5% glucose to a final concentration of 0.1%.

Primary Outcome Measure Information:

Title

Mean Change in Visual Acuity (Logarithm of the Minimum Angle of Resolution [LogMAR]) Score From Baseline for IGIV-C, 10% Compared to Placebo at Week 12 or at Last LogMAR Assessment (Conducted at or After Week 8 of the Treatment Period)

Description

Using the LogMAR score, lower values correspond to higher visual acuity. For example, a visual acuity of 20/20 corresponds to a LogMAR value of zero (0), and a visual acuity of 20/100 corresponds to a LogMAR value of 0.7.

Time Frame

At Week 12 or, if the Week 12 assessment is not available, at the last LogMAR assessment conducted at or after Week 8 of the Treatment Period

Secondary Outcome Measure Information:

Title

Proportion of Subjects Who Improve Visual Acuity From Baseline to Endpoint by ≥ 0.1 LogMAR

Time Frame